| 8.30 | |
Registration & Coffee
|
| 9.00 | |
Chairman's Opening RemarksDave Shelton, Senior Director, Pfizer Global Research & Development |
| 9.10 |  |
Translational mechanistic pain biomarkersLars Arendt-Nielsen, Director, Aalborg University View Bio
- Phase I and II proof-of-concept
- Pharmacodynamics &Mechanism based drug profiling
- Healthy volunteer studies
- Proof-of-mechanism
- Translation of animal data into pain patients
|
| 9.50 | |
Human tissues as a translational tool in pain research and target identificationFiona Boissonade, Head of Neuroscience Research Group, The University Of Sheffield View Bio
- Studies of neuropathic pain
- Studies of inflammatory pain
- Correlation with pre-clinical models
|
| 10.30 | |
Morning Coffee
|
| 10.50 | |
Imaging the common brain substrates of chronic pain- it’s all anticipationAnthony Kenneth Peter Jones, Professor of Neuro-Rheumatology, University of Manchester
- Recent research to suggest that fundamental changes in physiology of chronic pain sufferers may alter their PD compared to experimental models of healthy patients
- Can this research help to illuminate better ways at predicting drug PD in patients?
- How do these physiological changes relate to pain?
|
| 11.30 | |
Translation of Preclinical Pain Models - what is missing?Sigal Meilin, Scientific Director, MD Biosciences View Bio
- Current approach to developing pain therapies relies on mechanistic approach, however neuropathic pain in humans is rarely caused by a simple event
- Commonly pain studies ignore the fact that pain is a complex process
- New approach needs to consider relevant species, clinically relevant measures and understanding the emotional, learning and memory aspect of pain
|
| 11.55 | |
Novel targets in inflammatory and neuropathic pain Peter McNaughton, Head of Pharmacology Department, Cambridge University View Bio
- Inflammatory and neuropathic pain poorly treated by current analgesics – poor efficacy and many side effects
- Recent work in the McNaughton lab has identified the HCN2 ion channel and the AKAP79 scaffolding protein as potential targets
- Progress towards developing selective drugs
- Inflammatory and neuropathic pain poorly treated by current analgesics – poor efficacy and many side effects
- Recent work in the McNaughton lab has identified the HCN2 ion channel and the AKAP79 scaffolding protein as potential targets
- Progress towards developing selective drugs
|
| 12.35 | |
Opiate development: how efficacy, side-effect profiling, and target engagement can be rapidly and cost-effectively established in Phase IJohn Connell, Vice President Clinical Pharmacodynamics, ICON Development Solutions View Bio
- Can human pain models indicate efficacy in patients?
- Role of PK-PD modeling and simulation in guiding dose selection for patient trials
- What side effects of opiates can reasonably be explored in a healthy volunteer
- Impact of FDA guidelines on opiate-abuse on early phase opiate development
|
| 13.00 | |
Networking Lunch
|
| 14.00 | |
Challenges in analgesic drug discoveryNarender Gavva, Scientific Director, Amgen View Bio
- Emphasis is on preclinical discovery
- Potential false-positive hotspots
- Best practices for target selection criteria
|
| 14.40 | |
The use of anti-NGF agents in painDave Shelton, Senior Director, Pfizer Global Research & Development
- Novel approach to treating pain
- anti-NGF in clinical trials
- Challenges faced
- Future of anti-NGF agents
|
| 15.20 | |
Afternoon Tea
|
| 15.40 | |
CASE STUDY: Phase 3 and phase 4 trial experience with Exparel for prolonged post operative analgesia Gary Patou, Chief Medical Officer, Pacira Pharmaceuticals Inc View Bio
- Overview of Exparel and its mode of action
- Discussion of the trial methodology used for drug approval
- Phase 4 demonstration of health outcomes
|
| 16.20 | |
CASE STUDY: Focus on Nav1.7 blockers for chronic painValerie Morisset, Head of Electrophysiology, Convergence Pharmaceuticals View Bio
- Overview of Nav1.7 blockers field
- Preclinical properties of Nav1.7 blocker CNV1014802 / comparison with anti convulsants used in the clinic
- Clinical development
|
| 17.00 | |
Chairman’s Closing Remarks and Close of Day Two
|